Evidence map›Paper›PMID 40467894›Full record

ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025

Botulinum toxin in fracture management: a scoping review.

Emmanuel Spanoudakis, Themistoklis Vampertzis, Farokh Wadia, Darius Rares Rad, Christina Barmpagianni, Ioannis A Zervos, Eleftherios Tsiridis, Nikiforos Galanis

Abstract readScoping Review
In one paragraph

Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Emmanuel SpanoudakisUniversity Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. e.span98@yahoo.com.
Themistoklis VampertzisAristotle University of Thessaloniki, Thessaloniki, Greece. themisvamper@yahoo.com.
Farokh WadiaUniversity Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Darius Rares RadUniversity Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.
Christina BarmpagianniSurrey and Borders Partnership NHS Foundation Trust, Leatherhead, United Kingdom.
Ioannis A ZervosAristotle University of Thessaloniki, Thessaloniki, Greece.
Eleftherios TsiridisPapageorgiou General Hospital, Thessaloniki, Greece.
Nikiforos GalanisAristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUsing botulinum toxin (BoNT) as an adjunct in fracture management is a novel approach with the potential to improve clinical outcomes, particularly in atypical fractures and patients with concurrent neuromuscular disorders. This scoping review explores the literature on BoNT's effectiveness in facilitating fracture healing and immobilisation across various fracture types.

methodsThe PubMed, Embase, and Cochrane databases were searched with defined operators. Two investigators conducted independent searches, which were combined. Animal studies, case reports, case series, cohort reviews and randomised control trials were included.

resultsFifty studies were identified for screening, from which 15 studies were included in the review. The findings highlight mixed outcomes in BoNT's role in enhancing bone healing and reducing muscle-induced displacement. While BoNT injections demonstrated potential benefits in specific cases, such as atypical fractures, periprosthetic fractures and fractures in patients with motor dysfunctions, results from animal studies were inconsistent, showing varied effects on callous formation and bone mineral density.

conclusionClinical applications of BoNT in fracture management indicate its utility as an immobilisation agent to promote fracture healing and reduce complications. However, this review highlights that further research is necessary to bridge the gap between experimental and clinical studies and to clarify BoNT's effectiveness in different use cases.

Indexed as

Botulinum ToxinsFracture HealingFractures, BoneNeuromuscular AgentsAnimalsHumansBotulinum ToxinsNeuromuscular AgentsBotulinum toxinFracture healingFracture immobilisationMaxillofacial fracturesMuscle paralysisOrthopaedic trauma

Identifiers

PMID40467894
PMCPMC12137460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.